Drug overpricing: Govt plans amnesty scheme to recover dues from pharma companies

In a bid to tackle overpricing in the pharmaceutical sector, the government is planning an amnesty scheme to recover dues from pharmaceutical companies, CNBC Aawaz reported.

The National Pharmaceutical Pricing Authority (NPPA), responsible for overseeing drug pricing, has identified a substantial 2,200 cases of overpricing within the pharmaceutical industry.

Among the companies under scrutiny for overpricing practices are well-known names such as Cipla, Sun Pharma, and Lupin. These cases collectively involve dues amounting to approximately Rs. 13,000 crore.

The amnesty scheme proposes relief for pharmaceutical companies, offering waivers on interest and penalties associated with the alleged overpricing issues.

Pharma makers get a year for GMP implementation, Mandaviya warns action on defaults

The primary objective of the amnesty scheme is to recover outstanding dues from these companies. It is estimated that the government aims to retrieve around Rs. 5,000 to 6,000 crore through this initiative.

How are drug prices regulated?

Periodically, the Health Ministry collaborates with experts to create the National List of Essential Medicines (NLEM). This list includes medications vital for treating prevalent conditions and falls under price control through the Drug Price Control Order (DPCO).

The NPPA, a part of the Indian Government, was established to regulate drug prices. It enforces pricing and availability of medicines as per the Drugs (Prices Control) Order, 1995. NPPA also recovers overcharged amounts from consumers and monitors prices of unregulated drugs to ensure affordability.

Related Posts

‘Did patients come dancing?’ – Rajasthan minister’s remarks about kidney failure case spark row

On Thursday, Congress workers held protests against the “degrading medical conditions of Rajasthan” and attempted to enter the hospital premises. Rajasthan Health Minister Gajendra Singh Khinvsar’s remarks about women diagnosed…

Price cap on 2 key cancer drugs increased by 50%

NEW DELHI: Amid concerns over shortages of two critical cancer medicines, National Pharmaceutical Pricing Authority has approved a 50% hike in ceiling prices of Carboplatin and Cisplatin injections, citing escalating…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

‘Did patients come dancing?’ – Rajasthan minister’s remarks about kidney failure case spark row

‘Did patients come dancing?’ – Rajasthan minister’s remarks about kidney failure case spark row

Price cap on 2 key cancer drugs increased by 50%

Price cap on 2 key cancer drugs increased by 50%

Hospitals can’t force patients to buy medicines from their pharmacies: Maha FDA

Hospitals can’t force patients to buy medicines from their pharmacies: Maha FDA

IIT Bhubaneswar researchers develop portable device for accurate arsenic detection

IIT Bhubaneswar researchers develop portable device for accurate arsenic detection

Bribe of Rs 3 crore: Delhi Police inspector held, senior public servant under CBI scanner

Bribe of Rs 3 crore: Delhi Police inspector held, senior public servant under CBI scanner

No raids till further orders: Maharashtra tells Bombay HC in Patanjali labelling case

No raids till further orders: Maharashtra tells Bombay HC in Patanjali labelling case